Anal Carcinoma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Anal Carcinoma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

  • Transparency Market Research
  • Ongoing
  • Pharmaceutical

Report Description


Anal carcinoma is defined as the cancer of terminal part of the large intestine, starting at the upper surface of the rectal disc and passing through the genital floor to end at the anal canal. Anal carcinoma accounts for 2.5% of all digestive system distortions. Around 7000 new cases are detected in the U.S. every year. The incidence of anal carcinoma in the general public has increased over the last few decades, from 10 to around 20 per million individuals. Anal carcinoma has higher rate of incidence in women infected with human immunodeficiency virus (HIV), human papillomavirus (HPV), or genital warts. Factors such as receptive anal intercourse, cigarette smoking, and high lifetime number of sexual partners may also cause anal carcinoma. 

The global market for anal carcinoma treatment can be segmented based on type, treatment, end-user, and geography. Based on type, anal carcinoma treatment market has been categorized into perianal skin cancers, adenocarcinomas, anal melanomas, squamous cell carcinomas, and others. Based on treatment, the global market for anal carcinoma treatment has been categorized into surgery, radiation therapy, chemotherapy, and others. Based on end-user, anal carcinoma treatment market has been divided into hospitals, cancer treatment centers, and research institutes. Perianal glands tumor or perianal skin cancer is a type of tumor that is found near the anus, which develops from a particular glandular tissue found in the perineum. Adenocarcinoma is a kind of cancer that can arise in several places in the body and that can develop in mucus-secreting glands throughout the body. Anal melanoma is an aggressive and rare malignancy. Individuals suffering from anal melanoma usually exhibit a progressive and even metastatic disorder. Anal melanoma has no known risk factors unlike cutaneous melanoma. Squamous cell carcinoma is the most common type of anal carcinoma. It accounts for about 75% of anal cancer cases. 

Moreover, anal carcinoma is treated with surgeries that include removal of affected glandular tissues and some adjacent part of tissues. Minimally invasive surgical treatment procedures help minimize the risk of infection and reduce the healing time required. Chemotherapy drugs are either given orally or injected trough the intravenous or intramuscular route. They travel through the body and reach the site of action to kill cancerous cells. Radiation therapy has been classified into two basic types: internal beam radiation technology and external beam radiation technology. Internal radiation is directly injected into the areas affected by cancerous cells. 
Based on geography, the anal carcinoma treatment market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America anal carcinoma treatment market has been segmented into the U.S. and Canada. The Europe anal carcinoma treatment market has been segmented into the U.K., Germany, France, Italy, Spain, and Rest of Europe. The Asia Pacific anal carcinoma treatment market has been further divided into Japan, India, China, Australia & New Zealand, and Rest of Asia Pacific. The Latin America anal carcinoma treatment market has been segregated into Mexico, Brazil, and Rest of Latin America. The Middle East & Africa anal carcinoma treatment market has been segmented into Saudi Arabia, South Africa, Israel, and Rest of Middle East & Africa. North America dominates the global anal carcinoma treatment market, due to rising geriatric population and increasing demand for rapid diagnosis and better treatment among patients in the region. Presently, the U.S. is a key contributor to growth of the global anal carcinoma treatment market in North America. The global anal carcinoma treatment market is expected to expand at a significant rate in the next few years. Europe is the second-largest market for anal carcinoma treatment. Anal cancer affects around 1300 individuals in the U.K. every year. 

Some of the key players operating in the global anal carcinoma treatment market are Global BioPharma, Inc. Spectrum Pharmaceuticals, Inc., Advaxis, Inc. Pfizer Inc., and GlaxoSmithKline plc. 

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Have query on this report?

Make an Enquiry

Success Stories

Our Clients